In this study researchers are trying to find out why certain cancers stop responding to treatment with the class of drugs called PARP inhibitors.PARP inhibitors are a type of targeted cancer drug. For some women PARP inhibitors stop working and this is known as becoming resistant. Researchers want to collect samples of blood and tumour to find out …
In this study, researchers want to test a new blood test that they have developed which can tell doctors if a person is responding to the drug bevacizumab. Bevacizumab is a type of targeted therapy that works by blocking a growth factor (like a hormone) that makes blood vessels. This growth factor is called VEGF. By blocking VEGF, some cancers i…
Around half of women diagnosed with ovarian cancer are over the age of 65. Older women may have different medical and social problems than those seen in younger women. This may result in them being offered less intensive chemotherapy options to treat their ovarian cancer. Research has already shown that in older people who don’t have cancer, und…
The FORECEE (4C) research project is a new major study investigating the risk of breast, ovarian, womb and cervical cancer. Hormones are known to drive the development of particular diseases in women. Cervical cells are sensitive to the body’s own hormone levels in ways that are similar to the breast and other reproductive organs. This means tha…
Genetic testing in ovarian cancer patients is now being implemented across the NHS. It's hoped that by doing this, patients across the NHS will have even better treatments and that in some families, cancers will be prevented.In this study researchers want to find out about:what effect genetic counselling has on a person's emotional wellbeingwhat g…
Gynaecological cancer patients are all managed within 34 Cancer Centres located across the UK. These centres are only likely to see 1–5 new patients per year with rare gynaecological cancers. The low numbers of these cancers means that no single doctor or centre in the UK (or internationally) can hope to gain sufficient experience to be able to con…
Sign up to receive emails and keep up to date on all things Target Ovarian Cancer
Sign up
